Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.67 |
| ▸ | HPGD | P15428 | 6/20 | 0.67 |
| ▸ | MAPT | P10636 | 5/20 | 0.67 |
| ▸ | RAB9A | P51151 | 5/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.67 |
| ▸ | NPC1 | O15118 | 5/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.67 |
| ▸ | STAT1 | P42224 | 1/20 | 0.67 |
| ▸ | LDHA | P00338 | 1/20 | 0.66 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.66 |
| ▸ | HTT | P42858 | 3/20 | 0.58 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.58 |
| ▸ | NPY5R | Q15761 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.54 |
| ▸ | TP53 | P04637 | 1/20 | 0.54 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.54 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.54 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15245183 | 0.93 | KDM4E (0.62) | KDM4EHPGDMAPTRAB9AALDH1A1 | |
| SCHEMBL11219267 | 0.88 | MAPT (0.70) | KDM4EHPGDMAPTRAB9AALDH1A1 | |
| SCHEMBL3335842 | 0.83 | KDM4E (0.76) | KDM4EHPGDMAPTRAB9AALDH1A1 | |
| SCHEMBL3424059 | 0.82 | MAPT (0.67) | KDM4EHPGDMAPTRAB9AALDH1A1 | |
| SCHEMBL10175464 | 0.82 | CYP11B1 (0.79) | KDM4EHPGDMAPTRAB9AALDH1A1 | |
| SCHEMBL3541175 | 0.82 | MAPT (0.79) | KDM4EHPGDMAPTRAB9AALDH1A1 | |
| SCHEMBL8054731 | 0.82 | MAPT (0.67) | KDM4EHPGDMAPTRAB9AALDH1A1 | |
| SCHEMBL7164761 | 0.81 | RHEB (0.69) | KDM4EHPGDMAPTRAB9AALDH1A1 | |
| SCHEMBL3336441 | 0.81 | KDM4E (0.59) | KDM4EHPGDMAPTRAB9AALDH1A1 | |
| SCHEMBL15427088 | 0.81 | MAPT (0.57) | KDM4EHPGDMAPTRAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8198307-B2 | Imidazole derivatives having aryl piperidine substituent, method for preparation thereof and pharmaceutical compositions containing same | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2012-06-12 | — | — | US | disclosed |
| US-20100145054-A1 | IMIDAZOLE DERIVATIVES HAVING ARYL PIPERIDINE SUBSTITUENT, METHOD FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2010-06-10 | — | — | US | disclosed |
| WO-2007117778-A9 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS INC (US) | 2009-05-22 | — | — | WO | disclosed |
| EP-1986747-A2 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | Kalypsys, Inc. (US) | 2008-11-05 | — | — | EP | disclosed |
| US-20080139558-A1 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2007117778-A2 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | KALYPSYS, INC. (US) | 2007-10-18 | — | — | WO | disclosed |
| US-4336257-A | XANTHINE OXIDASE INHIBITORS OR ANTIHYPERTENSIVE AGENTS | MERCK & CO., INC. (US) | 1982-06-22 | — | — | US | disclosed |
| US-4281005-A | XANTHINE OXIDASE INHIBITORS AND AS ANTIHYPERTENSIVE | MERCK & CO., INC. (US) | 1981-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139558-A1 | QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS | NOS2, NOS1, NQO2 | KDM4E 3053/4885HPGD 13/4885MAPT 4128/4885 |
| US-20100145054-A1 | IMIDAZOLE DERIVATIVES HAVING ARYL PIPERIDINE SUBSTITUENT, METHOD FOR PREPARATION THEREOF AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | TYR, MCHR1, MCHR2 | KDM4E 220/4885HPGD 527/4885MAPT 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.